
With the support of BGM Associates, DuChemBio Co. Ltd. – the leading radiopharmaceutical company in South Korea – has entered into a strategic partnership and licensing agreement with Cyclotek for Australian and New Zealand markets. The agreement will provide Cyclotek with exclusive rights to commercialize Parkinson’s disease diagnostic tracer - [18F]FP-CIT.
[18F]FP-CIT is a radio-pharmaceutical tracer developed by nuclear medicine team at Asan Medical Center – one of the largest hospitals in South Korea. The tracer is intended for Positron Emission Tomography (PET) imaging of patients being evaluated for uncertain Parkinsonian syndrome. The product is an alternative to GE Healthcare’s DaTscan, and offers a clinical advantage over GE’s product thanks to the different imaging modality – PET instead of Single Photon Emission Computed Tomography (SPECT).
The agreement serves as the first step for DuChemBio and AMC to bring the proprietary tracer to the global markets with the support of BGM Associates.
Link to Asan Medical Center’s official announcement (in Korean)
[18F]FP-CIT is a radio-pharmaceutical tracer developed by nuclear medicine team at Asan Medical Center – one of the largest hospitals in South Korea. The tracer is intended for Positron Emission Tomography (PET) imaging of patients being evaluated for uncertain Parkinsonian syndrome. The product is an alternative to GE Healthcare’s DaTscan, and offers a clinical advantage over GE’s product thanks to the different imaging modality – PET instead of Single Photon Emission Computed Tomography (SPECT).
The agreement serves as the first step for DuChemBio and AMC to bring the proprietary tracer to the global markets with the support of BGM Associates.
Link to Asan Medical Center’s official announcement (in Korean)